News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trimeris, Inc. (TRMS) and F. Hoffmann-La Roche Ltd. (RHHBY) Amend Research Agreement Covering Next-Generation HIV Fusion Inhibitors


3/16/2007 2:38:14 AM

MORRISVILLE, N.C.--(BUSINESS WIRE)--Trimeris, Inc. (NASDAQ: TRMS) today announced that it has reached agreement with F. Hoffmann-La Roche Ltd (“Roche”) for the return of all rights to joint patents and other intellectual property related to next-generation HIV fusion inhibitor peptides to Trimeris that fall under the Roche-Trimeris 2000 Research Agreement. In return, Trimeris has agreed to pay Roche a nominal royalty on future net sales of TRI-1144 up to a specified limit.

Read at BioSpace.com


comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES